CanVECTOR Network

The debate over DOAC selection just got clearer. 🔍 The #COBRRA trial provides a definitive head-to-head look at bleeding risks in #VTE. Tomorrow, we explore the findings! Join the deep dive with @LanaCastellucci Register to attend🔗 bit.ly/4thelZT #Research

Susan Kahn is a leading voice in venous thrombosis & its long-term complications. Her work has helped shape patient care and clinical practice globally. Now honored with the 2026 ISTH Esteemed Career Award, she reflects on her career: isth.org/news/news.asp?…

In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period. Full COBRRA trial results and Research Summary: nejm.org/doi/full/10.10…

Dans le cadre d’une étude menée par la Dre Lana Castellucci, deux types d’anticoagulants souvent utilisés pour traiter la thromboembolie veineuse ont été comparés. L’un de ces médicaments a pu diminuer de plus de 50 % les cas d’hémorragie. cihr-irsc.gc.ca/f/54578.html?f…

A study led by Dr. Lana Castellucci compared two types of anticoagulants commonly used to treat venous thromboembolism and showed that one of the medications reduced bleeding by more than 50%. Learn more: cihr-irsc.gc.ca/e/54578.html?f… #BloodClotAwarenessMonth

Groundbreaking research at The Ottawa Hospital ctvnews.ca/ottawa/video/2…

🐍 COBRRA trial finds ↓ clinically relevant bleeding with apixaban vs. rivaroxaban during the first 3 months of treatment for acute VTE (RR 0.46, 95% CI 0.33–0.65)🩸 @uOttawaMed @OttawaHospital @CIHR_IRSC @INVENT_VTE

Ottawa Hospital research finds ‘clear winner’ for safer blood clot treatment ctvnews.ca/ottawa/article…

In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period. Full COBRRA trial results: nejm.org/doi/full/10.10…

Excited to share this fantastic new tool from @ASH_hematology trialmap.hematology.org TrialMap is the perfect resource for early-career clinician investigators. Guiding you from trial concept 💡 to practice-changing results 📄. A must-bookmark if launching a clinical trial!

In ARTESiA: Stroke ↓ 37% Major bleeding ↑ Fatal & intracranial bleeding: similar Understanding severity — not just frequency — changes the conversation. New episode of CLOT Conversations: thrombosiscan.info/CLOT-Conv53 #Anticoagulation #AFib #Thrombosis @DebSiegal

Can we safely rule out #DVT using age-adjusted D-dimer cutoffs? 🩺 Join our 1st 2026 Global Thrombosis Seminar! Dr. Grégoire Le Gal discusses the #ADJUST-DVT study (recently in @JAMA_current). 🗓️ Feb 25 🕘 14:00 UTC 🔗Register: bit.ly/3ONxyTZ #VTE #MedEd #Research

‼️So exciting to have one of my #BantingCanada postdoc projects, published last year in the #EuropeanHeartJournal, recognized among the Top 10 Research Papers of 2025 in the field of #CardioOncology 🙏🏼🎉 academic.oup.com/eurheartj/arti…

📣 NEWS: The ISTH announces five global recipients of 2026 Esteemed Career Awards! This award honors leaders in thrombosis and hemostasis whose life-long achievements have shaped the field through scientific excellence. Learn more: isth.org/news/news.asp?…

Join us for our upcoming National #Thrombosis Seminar on "Periprocedural Anticoagulation Management for Central Line Insertion in Persons with Cancer." Featuring: Dr. Jameel Abdulrehman - University of Toronto 📅 Feb 11 at 12:00 p.m. ET. Register: buff.ly/HPVWh1d

📢 Funding & Training Opportunities Applications are OPEN for the Fall 2025 #CanVECTOR competitions: ✅ Pilot Study Funding ✅ Research Start-Up Awards ✅ Fellowships PLUS: The Dr. Jack Hirsh Fellowship via @HamHealthSci & @McMasterU! 🔗 buff.ly/eXiHZ2o

Join us today at 12pm ET for our next National Thrombosis Seminar on "Biomarkers & Genetics for the Prediction of #VTE & Clinically Relevant Bleeding in Cancer Patients" - Featuring: Danielle Roy, PhD Register: buff.ly/MzRb0MT #Thrombosis #Research

🩺🧠 I will be chairing this Morning Report–style thrombosis cases, discussed live by an expert panel seeing the cases for the first time. 🎯 Perfect for thrombosis nerds 💻 Free & open to all. Register now! 👇 Hosted by @ThrombosisCan 🩸 #Thrombosis #MedEd

New CPD Webinar: Clinical Challenges in Thrombosis II Live, unscripted cases. Real-time expert discussion. March 3 | 7:00 PM ET Register: thrombosiscan.info/ClinicalChall

Join us for the next National Thrombosis Seminar on "Biomarkers & Genetics for the Prediction of #VTE & Clinically Relevant Bleeding in Cancer Patients" - featuring Danielle Roy, PhD 🗓️ Jan 15 - 12:00 p.m. ET. Register for free: buff.ly/MzRb0MT #Thrombosis #Research